Benitec Biopharma Limited announced that it has made strategic changes to its Board and management as part of an organizational restructure. This restructure reflects the strengthening commitment and confidence of Benitec's major shareholder, Nant Capital LLC (Nant). The company has reached an in-principle agreement with Dr. Jerel Banks for his transition, from Non-Executive Chairman, to Executive Chairman of the company effective immediately.

Dr. Banks first joined the Board of Benitec as a Non-Executive Director in October 2016 and became Chairman in October 2017. Dr. Banks initially became involved with Benitec as part of the strategic engagement between Benitec and Nant. To assist in the administration and management of Benitec's Australian operations, the company has reached an in-principle agreement with Ms. Megan Boston for her transition from a Non-Executive Director to an Executive Director and Head of Operations Australia.

Benitec announced the resignation of Dr. David Suhy from the role of Chief Scientific Officer, effective 22 June 2018. It is proposed that Dr. Suhy will continue as a consultant to Benitec on terms to be agreed. Benitec also announced that Mr. Greg West has resigned as CEO of Benitec with immediate effect.

Mr. West has been with Benitec for 7 years in the capacities of CEO, Company Secretary and CFO. Mr. West has made a significant contribution during his time at the company, most notably, securing Nant as a major investor.